Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Set To launch Aricept Generic In U.S. As FDA OKs Ohm Labs Data; Will Lipitor Be Next ?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest drug maker Ranbaxy - now part of Japanese pharma Daiichi Sankyo - is set to launch a generic version of the blockbuster Alzheimer's disease drug Aricept (donepezil) in the U.S. market, leading experts to predict that Ranbaxy may also be on track to launch a generic of the world's best selling drug, Lipitor (atorvastatin)

You may also be interested in...



The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?

MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel